
New Delhi, 25 April 2020
As per news report of Reuters, preliminary findings from the randomized trial of the antiviral drug remdesivir, begun in February by the National Institute of Allergy and Infectious Diseases (NIAID), could come even sooner, lead researcher Dr. Andre Kalil told Reuters in an interview.
Source -Reuters
If you like the story and if you wish more such stories, support our effort Make a donation.


Sat Apr 25 2020 | By Newsdesk

Sat Apr 25 2020 | By Newsdesk

Sat Apr 25 2020 | By Newsdesk

Sat Apr 25 2020 | By Newsdesk